Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
55
MGX Quote, Financials, Valuation and Earnings
Last price:
$1.69
Seasonality move
:
7.96%
Day range:
$1.67 - $1.73
52-week range:
$1.23 - $4.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.10x
P/B ratio:
0.37x
Volume:
161.3K
Avg. volume:
380.1K
1-year change:
-57.82%
Market cap:
$65.3M
Revenue:
$52.3M
EPS (TTM):
-$2.38
Analysts' Opinion
-
Consensus RatingMetagenomi, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.33, Metagenomi, Inc. has an estimated upside of 436.4% from its current price of $1.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $1.70.
Fair Value
-
According to the consensus of 5 analysts, Metagenomi, Inc. has 436.4% upside to fair value with a price target of $9.33 per share.
MGX vs. S&P 500
-
Over the past 5 trading days, Metagenomi, Inc. has overperformed the S&P 500 by 4.6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Metagenomi, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Metagenomi, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Metagenomi, Inc. reported revenues of $8.7M.
Earnings Growth
-
Metagenomi, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Metagenomi, Inc. reported earnings per share of -$0.55.
Enterprise value:
-77.1M
EV / Invested capital:
-0.35x
Price / LTM sales:
2.10x
EV / EBIT:
--
EV / Revenue:
-2.49x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
0.83x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$25.4M
Return On Assets:
-29.56%
Net Income Margin (TTM):
-287.06%
Return On Equity:
-41.18%
Return On Invested Capital:
-34.17%
Operating Margin:
-263.76%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $38M | $55.1M | $30.9M | $11.5M | $8.7M | |
| Gross Profit | $34.2M | $49.9M | $25.4M | $10.2M | $7.3M | |
| Operating Income | -$74.1M | -$88.5M | -$92.3M | -$22.4M | -$22.8M | |
| EBITDA | -$70.3M | -$83.3M | -$86.8M | -$21M | -$21.5M | |
| Diluted EPS | -$6.01 | -$2.50 | -$2.38 | -$0.51 | -$0.55 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $300M | $282.3M | $189.8M | |
| Total Assets | -- | -- | $386.4M | $358.3M | $247.9M | |
| Current Liabilities | -- | -- | $68.8M | $45.7M | $29.6M | |
| Total Liabilities | -- | -- | $154.7M | $102.6M | $69.5M | |
| Total Equity | -- | -- | $231.7M | $255.8M | $178.4M | |
| Total Debt | -- | -- | $45.9M | $41.4M | $36.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$103.4M | -$91.6M | -$26.6M | -$21.3M | |
| Cash From Investing | -- | -$56.1M | $99.7M | -$8.9M | $27.4M | |
| Cash From Financing | -- | $82.7M | -$430K | -$492K | -$187K | |
| Free Cash Flow | -- | -$107.9M | -$92.4M | -$27.8M | -$21.3M | |
MGX
Sector
Market Cap
$65.3M
$27.8M
Price % of 52-Week High
40.6%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
1.29%
-1.55%
1-Year Price Total Return
-53.85%
-17.47%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.70
200-day SMA
Sell
Level
$1.91
Bollinger Bands (100)
Sell
Level
1.63 - 2.57
Chaikin Money Flow
Buy
Level
243.3K
20-day SMA
Sell
Level
$1.72
Relative Strength Index (RSI14)
Sell
Level
44.60
ADX Line
Sell
Level
18.46
Williams %R
Neutral
Level
-50
50-day SMA
Sell
Level
$2.08
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
83M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0143)
Sell
CA Score
(Annual)
Level (-0.8675)
Buy
Beneish M-Score
(Annual)
Level (-2.7222)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.8767)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene editing toolbox, therapeutic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, MGX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MGX average analyst price target in the past 3 months is $9.33.
-
Where Will Metagenomi, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Metagenomi, Inc. share price will rise to $9.33 per share over the next 12 months.
-
What Do Analysts Say About Metagenomi, Inc.?
Analysts are divided on their view about Metagenomi, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Metagenomi, Inc. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Metagenomi, Inc.'s Price Target?
The price target for Metagenomi, Inc. over the next 1-year time period is forecast to be $9.33 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Metagenomi, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MGX?
You can purchase shares of Metagenomi, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Metagenomi, Inc. shares.
-
What Is The Metagenomi, Inc. Share Price Today?
Metagenomi, Inc. was last trading at $1.69 per share. This represents the most recent stock quote for Metagenomi, Inc.. Yesterday, Metagenomi, Inc. closed at $1.70 per share.
-
How To Buy Metagenomi, Inc. Stock Online?
In order to purchase Metagenomi, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MGX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MGX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
0.37x
1.82x
Price / LTM sales
2.10x
1.60x
Growth Metrics
MGX
Sector
Revenue growth
-24.8%
4.62%
Earnings growth
-6.93%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.53
-$0.21
Profitability
MGX
Sector
Profitability FY 2024
$46.9M
$3.5M
Return on invested capital
-34.17%
-31.77%
Return on assets
-29.56%
-27.96%
Return on equity
-41.18%
-37.63%
Earnings Date
Last Earnings Date
Aug
13
Next Earnings Date
Dec
27
Estimated Next Earnings Date
Mar
28
Balance Sheet
MGX
Sector
Total cash
$184.1M
$26.3M
Short term investments
$220.9M
$25.7M
Total assets
$324.6M
$78M
Long term debt
$36.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 27
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
